Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor replacement therapy has been the standard of care in hemophilia, although there are limitations to this approach. More recently, the approval of novel gene therapies has presented a promising option for patients with both hemophilia A and B.
In this podcast, you will hear from Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, and Johannes Oldenburg, MD, University Clinic Bonn, Bonn, Germany, who discuss the current standard of care in hemophilia and share some insights into the value of gene therapies.
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
Updates, challenges and novel agents being explored in BPDCN
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive